Category: Latest News
-
Camp4 Therapeutics Shares Slide After $30 Million Equity Offering Priced
Camp4 Therapeutics (NASDAQ:CAMP) shares dropped 8.6% on Thursday after the clinical-stage biotech company disclosed the pricing of a $30 million underwritten share offering. The company priced the sale of 5 million common shares at $6.00 each, with gross proceeds expected to total $30 million before underwriting fees and other expenses. The transaction is scheduled to…
-
Actelis Networks Shares Sink After Public Offering Priced at Steep Discount
Actelis Networks Inc. (NASDAQ:ASNS) shares plunged 47.8% on Thursday after the networking technology company disclosed the pricing of a public offering intended to raise $5 million. The company announced the sale of 6,250,000 shares of common stock, or pre-funded warrants, together with warrants to purchase up to an additional 6,250,000 shares. Each unit, consisting of…
-
Circle Internet Group Shares Rise After Strategic Partnership With Intuit
Circle Internet Group Inc. (NYSE:CRCL) shares gained 3.3% on Thursday after the digital financial services company unveiled a multi-year strategic collaboration with Intuit (NASDAQ:INTU), aimed at advancing next-generation financial products built around stablecoin technology. Shares of Intuit also moved higher, rising 1.5% following the announcement. Under the agreement, Intuit will integrate Circle’s stablecoin infrastructure and…
-
SailPoint Targets 2026 Expansion as CEO McClain Says AI’s ‘Real ROI’ Is Risk Reduction
SailPoint (NASDAQ:SAIL) is heading into 2026 with a strong sense of momentum, according to CEO Mark McClain, who told Investing.com this week that the most valuable returns from artificial intelligence are showing up in reduced security risk rather than simple cost efficiencies. In an exclusive discussion, McClain said consolidation in the cybersecurity and identity sectors…
-
Gold Prices Steady After Softer U.S. Inflation Print; Silver Pulls Back From Records
Gold prices held relatively steady on Thursday, while silver eased from recent record levels, as markets absorbed cooler-than-expected U.S. inflation data alongside a series of key central bank policy decisions. By 09:15 ET (14:15 GMT), spot gold was down 0.1% at $4,336.54 an ounce, while February gold futures also slipped 0.1% to $4,370.30 per ounce.…
-
Accenture Shares Rise After Q1 Results and Bookings Beat Forecasts
Accenture (NYSE:ACN) shares climbed 3.8% in premarket trading on Thursday after the consulting and professional services group delivered first-quarter results that exceeded market expectations, supported by solid revenue growth and a sharp increase in new client bookings. For the quarter ended November 30, 2025, Accenture reported adjusted earnings of $3.94 per share, beating analyst forecasts…
-
Etsy Shares Climb After Company Unveils $750 Million Buyback Program
Etsy Inc (NYSE:ETSY) shares rose 2.2% in premarket trading on Thursday after the online marketplace operator announced a new authorization to repurchase up to $750 million of its own stock. The company said that, when combined with more than $200 million still available under its existing buyback program, the new authorization brings Etsy’s total potential…
-
Trump Media Shares Jump on $6 Billion Merger Deal With TAE Technologies
Trump Media & Technology Group (NASDAQ:DJT) shares surged in premarket trading on Thursday, climbing about 27% to roughly $13.30 after the company announced plans to merge with privately held fusion energy developer TAE Technologies. The transaction, structured as an all-stock merger, places a valuation of more than $6 billion on the combined group. Under the…
-
Athira Pharma Shares Surge After Securing Rights to Phase 3 Breast Cancer Therapy
Athira Pharma Inc (NASDAQ:ATHA) shares soared 73.4% in premarket trading on Thursday after the clinical-stage biopharmaceutical company announced it has obtained worldwide rights to develop and commercialize lasofoxifene, a late-stage breast cancer drug currently being evaluated in Phase 3 trials. Athira has entered into an exclusive global licensing agreement with Sermonix Pharmaceuticals for the selective…
-
Soligenix Shares Jump on Encouraging Data for Behçet’s Disease Therapy
Soligenix Inc (NASDAQ:SNGX) shares rose 5.2% on Thursday after the company released positive findings from a Phase 2a clinical study evaluating SGX945 for the treatment of oral ulcers associated with Behçet’s Disease. The biopharmaceutical company reported that seven of the eight patients enrolled in the study experienced meaningful clinical benefits during the four-week treatment phase.…